CFD'er er komplekse instrumenter, og der er stor risiko for at miste penge hurtigt på grund af gearing. 84% af individuelle investorer taber penge, når de handler CFD'er med denne udbyder. Du bør overveje, om du forstår, hvordan CFD'er virker, og om du har råd til at løbe en høj risiko for at miste dine penge.

Scan to Download iOS&Android APP

Handel Denali Therapeutics - DNLI CFD

31.67
2.85%
0.09
Lav: 31.5
Høj: 32.67
Market Trading Hours* (UTC) Opens on Monday at 14:30

Mon - Fri: 14:30 - 21:00

  • Opsummering
  • Historisk Data
  • Begivenheder
  • Resultatopgørelse
  • Saldo
  • Cash flow
  • Ejerskab
Handelsbetingelser
Spænd 0.09
Long position, gebyr natten over

Long position overnight fee


Margin. Your investment $1,000.00
Gebyr for natten over -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Gå til platform
-0.030779%
Short position, gebyr natten over

Short position overnight fee


Margin. Your investment $1,000.00
Gebyr for natten over -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00

Gå til platform
-0.013666%
Gebyr natten over, tid 22:00 (UTC)
Min. handlet mængde 1
Valuta USD
Margen 20%
Aktiebørs United States of America
Kommission på handel 0%

*Information provided by Capital.com

Nøglestatistikker
Tidligere luk* 32.6
Åben* 32.49
1-Års Ændring* -4.19%
Dagens Spænd* 31.5 - 32.67
52-Ugers Spænd 20.24-39.43
Gennemsnitlig Volumen (10 dage) 623.19K
Gennemsnitlig Volumen (3 måneder) 13.58M
Market Cap 4.44B
P/E-forhold -100.00K
Udestående aktier 135.81M
Omsætning 110.69M
EPS -2.46
Dividend (Udbytte %) N/A
Beta 1.37
Næste indtjeningsopgørelse Feb 27, 2023

Al data kommer fra Refinitiv, med undtagelse af data markeret med en asterisk, som er *data fra Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Luk Change Change (%) Åben High Low
Feb 3, 2023 31.67 -0.17 -0.53% 31.84 32.76 31.47
Feb 2, 2023 32.60 1.57 5.06% 31.03 32.60 30.45
Feb 1, 2023 30.84 0.86 2.87% 29.98 31.37 29.97
Jan 31, 2023 30.20 0.22 0.73% 29.98 30.79 29.97
Jan 30, 2023 30.07 -1.42 -4.51% 31.49 31.71 29.93
Jan 27, 2023 31.44 0.97 3.18% 30.47 31.94 30.47
Jan 26, 2023 30.50 0.24 0.79% 30.26 31.02 30.01
Jan 25, 2023 30.76 0.65 2.16% 30.11 30.78 29.67
Jan 24, 2023 30.23 1.21 4.17% 29.02 30.58 28.97
Jan 23, 2023 29.65 0.63 2.17% 29.02 29.72 28.45
Jan 20, 2023 29.00 -0.56 -1.89% 29.56 29.56 28.58
Jan 19, 2023 29.18 -0.33 -1.12% 29.51 29.71 28.80
Jan 18, 2023 30.03 -0.21 -0.69% 30.24 30.85 29.67
Jan 17, 2023 30.06 1.09 3.76% 28.97 30.20 28.75
Jan 13, 2023 29.05 0.35 1.22% 28.70 29.56 28.62
Jan 12, 2023 29.16 1.53 5.54% 27.63 29.19 26.95
Jan 11, 2023 27.62 -0.20 -0.72% 27.82 27.98 26.73
Jan 10, 2023 28.06 0.54 1.96% 27.52 28.51 27.34
Jan 9, 2023 27.77 -0.59 -2.08% 28.36 28.69 27.72
Jan 6, 2023 28.83 0.25 0.87% 28.58 29.36 27.86

Denali Therapeutics Events

Time (UTC) Country Event
No events scheduled
View all events
  • Årlig
  • Pr kvartal
2016 2017 2018 2019 2020 2021
Total omsætning 0 0 129.16 26.678 335.659 48.661
Totale Driftsudgifter 87.433 90.14 175.532 239.862 272.941 344.412
Salgs/Generelle/Admin. Udgifter, Total 11.731 15.68 32.349 46.48 60.326 79.059
Forskning & Udvikling 75.702 74.46 143.183 193.382 212.615 265.353
Driftsindtægter -87.433 -90.14 -46.372 -213.184 62.718 -295.751
Renteindkomst (Udgift), Netto Ikke-Drift 0.781 1.955 10.132 15.219 9.241 4.595
Netto Indkomst Før Skat -86.652 -88.185 -36.24 -197.965 71.959 -291.156
Netto Indkomst Efter Skat -86.652 -88.185 -36.24 -197.614 71.136 -290.581
Netto Indkomst Før Ekstra Ting -86.652 -88.185 -36.24 -197.614 71.136 -290.581
Netto Indkomst -86.652 -88.185 -36.24 -197.614 71.136 -290.581
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -86.652 -88.185 -36.24 -197.614 71.136 -290.581
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -86.652 -88.185 -36.24 -197.614 71.136 -290.581
Fortyndelsesændring 0
Fortyndet Netto Indkomst -86.652 -88.185 -36.24 -197.614 71.136 -290.581
Fortyndet Vægtet Gennemsnit Aktier 82.4239 87.4804 92.622 95.6082 112.703 121.525
Fortyndet EPS Uden Ekstraordinære Ting -1.0513 -1.00805 -0.39127 -2.06691 0.63118 -2.39113
Dividends per Share - Common Stock Primary Issue 0
Fortyndet Normaliseret EPS -1.0513 -1.00805 -0.39127 -2.06691 0.63118 -2.39113
Omsætning 129.16 26.678 335.659 48.661
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total omsætning 7.923 22.939 5.285 12.514 42.141
Omsætning 7.923 22.939 5.285 12.514 42.141
Totale Driftsudgifter 79.143 84.756 90.878 89.635 108.639
Salgs/Generelle/Admin. Udgifter, Total 18.936 19.045 19.319 21.759 22.541
Forskning & Udvikling 60.207 65.711 71.559 67.876 86.098
Driftsindtægter -71.22 -61.817 -85.593 -77.121 -66.498
Renteindkomst (Udgift), Netto Ikke-Drift 1.179 1.126 1.005 1.285 1.278
Netto Indkomst Før Skat -70.041 -60.691 -84.588 -75.836 -65.22
Netto Indkomst Efter Skat -70.041 -60.691 -84.588 -75.261 -65.22
Netto Indkomst Før Ekstra Ting -70.041 -60.691 -84.588 -75.261 -65.22
Netto Indkomst -70.041 -60.691 -84.588 -75.261 -65.22
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -70.041 -60.691 -84.588 -75.261 -65.22
Indkomst Tilgængelig for Almindelige Uden Ekstra Ting -70.041 -60.691 -84.588 -75.261 -65.22
Fortyndet Netto Indkomst -70.041 -60.691 -84.588 -75.261 -65.22
Fortyndet Vægtet Gennemsnit Aktier 120.885 121.291 121.742 122.172 122.674
Fortyndet EPS Uden Ekstraordinære Ting -0.5794 -0.50037 -0.69481 -0.61603 -0.53165
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Fortyndet Normaliseret EPS -0.5794 -0.50037 -0.69481 -0.61603 -0.53165
  • Årlig
  • Pr kvartal
2016 2017 2018 2019 2020 2021
Totale Nuværende Aktiver 181.955 409.607 480.836 430.031 1495.66 897.234
Likvider og Kortsigtede Investeringer 178.331 406.226 464.297 415.356 1469.7 865.407
Likvider & Lignende 39.853 218.375 77.123 79.449 507.144 293.477
Kortsigtede Investeringer 138.478 187.851 387.174 335.907 962.553 571.93
Totale Tilgodehavender, Netto 0.438 0.464 1.182 5.674 1.226
Accounts Receivable - Trade, Net 0.438 0.464 1.182
Prepaid Expenses 3.186 2.917 15.357 14.675 20.284 30.601
Total Assets 271.067 486.721 661.984 553.231 1604.28 1404.16
Property/Plant/Equipment, Total - Net 15.262 14.923 25.162 80.655 73.464 69.608
Property/Plant/Equipment, Total - Gross 16.85 19.592 37.172 92.928 94.266 98.952
Accumulated Depreciation, Total -1.588 -4.669 -12.01 -12.273 -20.802 -29.344
Long Term Investments 73.08 61.25 147.881 39.886 32.699 425.449
Other Long Term Assets, Total 0.77 0.941 8.105 2.659 2.462 11.871
Total Current Liabilities 9.106 14.164 32.786 45.344 71.699 378.245
Accounts Payable 1.963 2.716 1.891 2.59 1.071 4.779
Accrued Expenses 6.442 10.53 18.472 24.007 47.145 53.165
Notes Payable/Short Term Debt 0 0 0 0 0 0
Other Current Liabilities, Total 0.701 0.918 12.423 18.747 23.483 320.301
Total Liabilities 16.548 20.925 115.139 158.341 453.749 441.871
Total Long Term Debt 0 0 0 0 0 0
Other Liabilities, Total 7.442 6.761 82.353 112.997 382.05 63.626
Total Equity 254.519 465.796 546.845 394.89 1150.53 962.291
Redeemable Preferred Stock 348.673 0 0 0 0 0
Common Stock 0.344 1.201 1.273 1.288 1.531 1.548
Additional Paid-In Capital 9.387 656.66 774.158 818.803 1503.66 1608.24
Retained Earnings (Accumulated Deficit) -103.512 -191.697 -227.937 -425.551 -354.415 -644.996
Other Equity, Total -0.373 -0.368 -0.649 0.35 -0.245 -2.499
Total Liabilities & Shareholders’ Equity 271.067 486.721 661.984 553.231 1604.28 1404.16
Total Common Shares Outstanding 82.4239 87.4804 94.6624 96.1899 120.531 122.283
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Totale Nuværende Aktiver 1431.62 1341.74 1055.51 897.234 988.436
Likvider og Kortsigtede Investeringer 1413.15 1308.93 1039.18 865.407 957.522
Likvider & Lignende 435.321 485.68 394.553 293.477 104.953
Kortsigtede Investeringer 977.827 823.251 644.622 571.93 852.569
Totale Tilgodehavender, Netto 2.511 16.785 1.194 1.226 0
Prepaid Expenses 15.963 16.029 15.14 30.601 30.914
Total Assets 1547.86 1509.81 1449.97 1404.16 1320.86
Property/Plant/Equipment, Total - Net 73.612 71.972 71.208 69.608 67.942
Long Term Investments 38.885 92.522 319.472 425.449 250.268
Other Long Term Assets, Total 3.739 3.576 3.777 11.871 14.212
Total Current Liabilities 54.61 51.412 54.251 378.245 341.24
Accounts Payable 1.626 4.235 4.817 4.779 3.358
Accrued Expenses 36.529 37.984 44.672 53.165 44.542
Notes Payable/Short Term Debt 0 0 0 0 0
Other Current Liabilities, Total 16.455 9.193 4.762 320.301 293.34
Total Liabilities 442.505 437.11 437.689 441.871 402.931
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 387.895 385.698 383.438 63.626 61.691
Total Equity 1105.35 1072.7 1012.28 962.291 917.927
Redeemable Preferred Stock 0 0 0
Common Stock 1.537 1.541 1.545 1.548 1.554
Additional Paid-In Capital 1528.5 1556.68 1580.99 1608.24 1635.84
Retained Earnings (Accumulated Deficit) -424.456 -485.147 -569.735 -644.996 -710.216
Other Equity, Total -0.232 -0.368 -0.521 -2.499 -9.251
Total Liabilities & Shareholders’ Equity 1547.86 1509.81 1449.97 1404.16 1320.86
Total Common Shares Outstanding 121.147 121.532 122.011 122.283 122.858
  • Årlig
  • Pr kvartal
2016 2017 2018 2019 2020 2021
Netto indkomst/Startlinje -86.652 -88.185 -36.24 -197.614 71.136 -290.581
Likvider Fra Driftsaktiviteter -71.908 -76.635 50.116 -151.576 416.152 -211.389
Likvider Fra Driftsaktiviteter 1.469 3.082 7.415 7.991 8.531 8.593
Ikke-Likvide Ting 8.538 5.163 16.05 33.872 50.444 93.995
Ændringer i Driftskapital 4.737 3.305 62.891 4.175 286.041 -23.396
Likvider fra Investeringsaktiviteter -219.004 -41.166 -287.422 147.712 -623.206 -21.626
Kapitaludgifter -6.134 -2.875 -3.393 -17.919 -3.095 -8.5
Andre Investerings-Cash-Flow-Ting, Total -212.87 -38.291 -284.029 165.631 -620.111 -13.126
Likvider fra Financieringsaktiviteter 300.476 296.323 97.019 6.19 634.749 19.348
Financiering af Cash-Flow-Ting 0 -1.386 0
Udstedelse (Pensionering) af Aktier, Netto 300.476 296.323 98.405 6.19 634.749 19.348
Netto Ændring i Likviditet 9.564 178.522 -140.287 2.326 427.695 -213.667
Udstedelse (Pensionering) af Gæld, Netto 0
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -70.041 -130.732 -215.32 -290.581 -65.22
Cash From Operating Activities -50.24 -104.461 -145.895 -211.389 -72.109
Cash From Operating Activities 2.108 4.312 6.499 8.593 2.079
Non-Cash Items 21.496 44.401 67.277 93.995 26.989
Changes in Working Capital -3.803 -22.442 -4.351 -23.396 -35.957
Cash From Investing Activities -25.405 72.132 19.124 -21.626 -117.878
Capital Expenditures -2.8 -3.572 -5.447 -8.5 -4.041
Other Investing Cash Flow Items, Total -22.605 75.704 24.571 -13.126 -113.837
Cash From Financing Activities 3.822 10.865 14.18 19.348 1.463
Issuance (Retirement) of Stock, Net 3.822 10.865 14.18 19.348 1.463
Net Change in Cash -71.823 -21.464 -112.591 -213.667 -188.524
Investornavn Investortype Procent udestående Aktiebeholdning Aktieændring Beholdningsdato IOmsætningsscore
Baillie Gifford & Co. Investment Advisor 11.1325 15119474 404423 2022-12-31 LOW
Biogen Inc Corporation 9.8004 13310243 0 2022-03-31 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.1736 8384653 101661 2022-09-30 LOW
Crestline Investors, Inc. Hedge Fund 5.2725 7160732 -300000 2022-09-30 HIGH
BlackRock Institutional Trust Company, N.A. Investment Advisor 5.1599 7007844 -275665 2022-09-30 LOW
Temasek Holdings Pte. Ltd. Sovereign Wealth Fund 4.1057 5576041 206554 2022-09-30 LOW
State Street Global Advisors (US) Investment Advisor/Hedge Fund 3.0867 4192228 441528 2022-09-30 LOW
ARCH Venture Partners Venture Capital 2.7013 3668749 -1500000 2022-09-30 LOW
T. Rowe Price Associates, Inc. Investment Advisor 2.5073 3405263 -1204914 2022-09-30 LOW
Flagship Ventures Venture Capital 1.9291 2619968 0 2022-09-30 LOW
Fidelity Management & Research Company LLC Investment Advisor 1.8058 2452456 -417284 2022-09-30 LOW
Watts (Ryan J) Individual Investor 1.6807 2282637 82240 2023-01-03 LOW
Tessier-Lavigne (Marc) Individual Investor 1.55 2105151 -40000 2022-11-23 LOW
Gilder Gagnon Howe & Co. LLC Hedge Fund 1.3719 1863277 -93543 2022-09-30 LOW
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.3078 1776164 69583 2022-09-30 LOW
Credit Suisse Asset Management Investment Advisor/Hedge Fund 1.1858 1610492 -349178 2022-09-30 LOW
Mellon Investments Corporation Investment Advisor/Hedge Fund 0.917 1245479 15816 2022-09-30 LOW
Yiheng Capital Management, L.P. Investment Advisor 0.7471 1014684 0 2022-09-30 LOW
Pictet Asset Management Ltd. Investment Advisor/Hedge Fund 0.7386 1003185 -11973 2022-09-30 LOW
Casdin Capital, LLC Hedge Fund 0.7326 995000 -505000 2022-09-30 LOW

Hvorfor vælge Capital.com? Vores tal taler for sig selv.

Capital.com Group
+485000+

Handlende

65000+

Månedlkige, aktive klienter

$48000000+

Månedlig investeringsvolumen

$28000000+

Hævet hver måned

Handelslommeregner

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Handelskurtage
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Gearing
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investering
Handelsstørrelse (Gearing x Investering):
Åben

Luk

Short Long

Denali Therapeutics Company profile

Om Denali Therapeutics

Denali Therapeutics Inc. er en biofarmaceutisk virksomhed. Virksomheden fokuserer på opdagelse og udvikling af behandlinger til patienter med neurodegenerative sygdomme, herunder Alzheimers sygdom, Parkinsons sygdom, amyotrofisk lateralsklerose (ALS) og andre. Virksomhedens kliniske programmer omfatter et program for hæmmer af leucinrig gentaget kinase 2 (LRRK2), et program for aktivator af eukaryotisk initieringsfaktor 2 B (EIF2B), et program for enzymtransportmiddel: iduronat 2-sulfatase (ETV:IDS), et program for hæmmer af receptorinteragerende serin/threoninproteinkinase 1 (RIPK1) og en anden ikke-CNS penetrerende RIPK1-hæmmer. Virksomheden udvikler sine produktkandidater til at krydse blod-hjernebarrieren (BBB) og virke direkte i hjernen. Virksomhedens pipeline omfatter ca. 15 programmer, der er baseret på virksomhedens TV-teknologi, herunder det førende program ETV:IDS (DNL310). Produktpipelinen omfatter DNL151, DNL593 (PTV:PGRN), DNL126 (ETV:SGSH), DNL788, DNL343 og DNL758,

Industry: Bio Therapeutic Drugs

161 Oyster Point Blvd
SOUTH SAN FRANCISCO
CALIFORNIA 94080-1910
US

Resultatopgørelse

  • Annual
  • Quarterly

Folk ser også

Natural Gas

2.41 Price
-2.390% 1D Chg, %
Long position, gebyr natten over -0.1138%
Short position, gebyr natten over 0.0796%
Gebyr natten over, tid 22:00 (UTC)
Spænd 0.005

XRP/USD

0.41 Price
+0.170% 1D Chg, %
Long position, gebyr natten over -0.0500%
Short position, gebyr natten over 0.0140%
Gebyr natten over, tid 22:00 (UTC)
Spænd 0.00272

Oil - Crude

73.41 Price
-3.570% 1D Chg, %
Long position, gebyr natten over -0.0223%
Short position, gebyr natten over 0.0065%
Gebyr natten over, tid 22:00 (UTC)
Spænd 0.03

US100

12,566.80 Price
-0.450% 1D Chg, %
Long position, gebyr natten over -0.0183%
Short position, gebyr natten over 0.0071%
Gebyr natten over, tid 22:00 (UTC)
Spænd 3.0

Leder du stadig efter en mægler, du kan stole på?

Deltag sammen med 485.000+ handlende over hele verden, der valgte at handle hos Capital.com

1. Opret og bekræft din konto 2. Lav en inddbetaling 3. Find din handel